← Eichor
Study identifier: NCT06437353 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Surufatinib Combined With Carboplatin/Paclitaxel and Surufatinib Combined With Olaparib as First-line and Maintenance Therapy for Newly Diagnosed High-risk Ovarian Cancer

Condition: Ovarian Cancer  ·  Sponsor: Anhui Provincial Cancer Hospital

PhasePhase 2
Planned participants74
Who can joinFemale, 18 Years to 75 Years
Healthy volunteersNo

About this study

The goal of this type of clinical trial study is to evaluate the safety and efficacy of Surufatinib combined with Carboplatin/Paclitaxel and Surufatinib combined with Olaparib as first-line and maintenance therapy for newly diagnosed high-risk ovarian cancer

This description comes directly from the study's public registry record.

Talk to the study team

Bairong Xia, Doctor  ·  18604516165  ·  xiabairong9999@126.com

Always discuss trial participation with your own doctor first.

Locations (1)

Anhui Cancer HospitalHefei, Anhui, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06437353